UNASSIGNED: Anti-Jo-1 is the most frequently detectable antibody in the antisynthetase syndrome (ASSD), an @entity792 characterized by the occurrence of @entity625 , @entity5442 , and @entity401 ( @entity401 ). Recently, we organized an international collaborative group called American and European NEtwork of Antisynthetase Syndrome (AENEAS) for the study of this @entity395 . The group collected and published one of the largest series of ASSD @entity1 ever described and with one of the longer follow-up ever reported. The number of participating centers is steadily increasing, as well as the available cohort. In the first paper, we showed that @entity625 , @entity5442 , and @entity401 may be frequently the only feature at disease onset, raising problems to reach a correct diagnosis of this syndrome. Nevertheless, we first observed that the ex novo appearance of further manifestations is common during the follow-up, strengthening the importance of a correct diagnosis. In our cohort, the 24  % of the 243 @entity1 up to now collected had @entity625 as a presenting feature. These @entity1 represent the most intriguing group in terms of differential diagnosis and clinical time course. Furthermore, data on this aspect are scanty, the reason that lead us to evaluate these aspects in our cohort of @entity1 , reviewing also available literature. In fact, the most relevant aspect is that ASSD is rarely suspected in this setting of @entity1 , in particular in case of poliarticular involvement, positive rheumatoid factor (RF), or anti-cyclic citrullinated peptide antibodies (ACPA) or evidence of joint @entity2681 at plain radiographs. These findings were not rare in our cohort, and they have been also described in other series. Furthermore, manifestations such as @entity2407 , mechanic's hands, and fever that may lead to the suspect of ASSD are observed only in a third of cases. If we consider the high rate of clinical picture progression in these @entity1 , we feel that ASSD should be carefully considered in all @entity1 presenting with @entity625 , even in those with erosive, RF, and ACPA-positive @entity625 .

Serum Jo-1 Autoantibody and XXXX in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group.

@entity395 :: ('MESH:D035583', 'Disease') :: ['rare and fascinating disease'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity5442 :: ('MESH:D009220', 'Disease') :: ['myositis'] @entity625 :: ('MESH:D001168', 'Disease') :: ['isolated arthritis', 'arthritis'] @entity2681 :: ('MESH:D014077', 'Disease') :: ['erosions'] @entity2407 :: ('MESH:D011928', 'Disease') :: ["Raynaud's phenomenon"] @entity401 :: ('MESH:D017563', 'Disease') :: ['ILD', 'interstitial lung disease'] @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disease']
@entity625 :: (MESH:D001168,Disease) :: ['Isolated Arthritis']
